As of May 27
| +0.56 / +2.09%|
The 13 analysts offering 12-month price forecasts for Genomic Health Inc have a median target of 32.00, with a high estimate of 40.00 and a low estimate of 20.00. The median estimate represents a +16.83% increase from the last price of 27.39.
The current consensus among 17 polled investment analysts is to Hold stock in Genomic Health Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.